Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: An effective and well-tolerated frontline regimen

European Journal of Haematology

Volumn 82, Issue 6, 2009, Pages 433-439

  Berenson, James R ^a,b,c   Yellin, Ori ^b   Woytowitz, Donald ^d   Flam, Marshall S ^e   Cartmell, Alan ^e   Patel, Ravi ^f   Duvivier, Herb ^c   Nassir, Youram ^g,h   Eades, Benjamin ^c   Abaya, Christina Dilauro ^b   Hilger, Jacqueline ⁱ   Swift, Regina A ^c  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Oncotherapeutics   (United States)

^c James R Berenson MD Inc   (United States)

^d Florida Cancer Specialists   (United States)

^e Hematology Oncology Medical Group   (United States)

^f Comprehensive Blood and Cancer Center ^*  (United States)

^g CEDARS SINAI MEDICAL CENTER   (United States)

^h Nassir Medical Corporation   (United States)

ⁱ MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Ascorbic acid; Bortezomib; Frontline therapy; Melphalan; Multiple myeloma

Indexed keywords

ASCORBIC ACID; BORTEZOMIB; MELPHALAN;

ADULT; AGED; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; HEART ATRIUM FLUTTER; HERPES ZOSTER; HUMAN; MAINTENANCE DRUG DOSE; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCORBIC ACID; BORONIC ACIDS; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65349193958     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01244.x     Document Type: Article

References (33)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD : National Cancer Institute, 2002.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 57 : 43 66.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996 335 : 91 7.
4. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003 348 : 1875 83.
5. Bladé J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005 106 : 3755 9.
6. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007 370 : 1209 18.
7. Hulin C, Facon T, Rodon P, et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007 110 : 31a.
8. Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006 76 : 273 7.
9. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 359 : 906 17.
10. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. Blood 2007 110 : 32a.
11. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007 110 : 3557 60.
12. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003 9 : 1136 44.
13. Mitsiades CS, Mitsiades N, McMullan CJ, et al. The proteasome inhibitor bortezomib (PS-341) is active against Waldenstrom's macroglobulinemia (WM). Blood 2003 102 : 181a.
14. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006 24 : 937 44.
15. Berenson JR, Yang HH, Vescio RA, et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol 2008 87 : 623 31.
16. Mateos M-V, Hernández J-M, Hernández M-T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008 93 : 560 5.
17. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006 108 : 2165 72.
18. May JM, Qu Z, Li X. Requirement for GSH in recycling of ascorbic acid in endothelial cells. Biochem Pharmacol 2001 62 : 873 81.
19. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001 98 : 805 13.
20. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991 51 : 995 1002.
21. Gupta V, Singh SV, Ahmad H, Medh RD, Awasthi YC. Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan. Biochem Pharmacol 1989 38 : 1993 2000.
22. Campbell RA, Sanchez E, Steinberg JA, et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007 138 : 467 78.
23. National Cancer Institute. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf.
24. Zou W, Yue P, Lin N, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006 12 : 273 80.
25. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998 102 : 1115 23.
26. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005 23 : 3412 20.
27. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 367 : 825 31.
28. Anderson K, Richardson P, Chanan-Khan A, et al. Single-agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study. J Clin Oncol 2006 24 : 423s.
29. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008 141 : 512 6.
30. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006 24 : 3113 20.
31. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of dose-modification guideline. Br J Haematol 2009 Jan 16 [Epub ahead of print].
32. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2007 110 : 31a.
33. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003 21 : 16 9.